The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Non-biopsy diagnostic strategies for primary CNS lymphoma
Maurilio Ponzoni, MD, of Vita Salute University San Raffaele, Milan, Italy, shares insights into alternative approaches for diagnosing primary central nervous system lymphoma (PCNSL), noting that while stereotactic biopsies are the gold standard, they are not always possible due to anatomical limitations. In that case, Prof. Ponzoni highlights that detecting the MYD88 mutation and elevated IL-10 levels can be useful diagnostic biomarkers, although this doesn’t have 100% accuracy. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
